Investors and stakeholders across the industry are keeping a close eye on a potential cancer drug target – TIGIT – that could be effective in combination with PD-1/L1 drugs. Several drug makers are investing in the class of drugs, which are in late-stage clinical testing, but the first Phase III data readout in the class of drugs from Roche Holding AG last year was disappointing, raising uncertainty about how other data readouts will play out.
Merck & Co., Inc. and Roche, two of the companies investing heavily in the area, both reported quarterly financial...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

